Ex vivo drug sensitivity testing predicts venetoclax+azacitidine treatment responses in AML. VenEx trial interim results presented at #ASH21

Excellent talk by @josephsaad95 on NAMPT inhibitors in AML with monosomy 7/del(7q) yesterday at #ASH22!

Ex vivo venetoclax sensitivity predicts responses in both de novo and s/R/R AML patients Kontro Lab #ASH22

Our newest paper "Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia" is now published and accessible Haematologica haematologica.org/article/view/h…

1/ Excited to share our study with Olli Dufva suggesting venetoclax resistance and BCL-XL dependence in erythroid/megakaryoblastic AML @BloodJournal doi.org/10.1182/blood.…

A clinical trial performed in Finland has shown that a drug sensitivity test performed on patient's own cells in laboratory conditions predicts patient's response to a new effective leukemia drug, venetoclax. The study was led by Mika Kontro & Heikki Kuusanmäki. helsinki.fi/en/hilife-hels…

Meet our K. Albin Johansson Cancer Researcher Heikki Kuusanmäki. Heikki has a versatile background in translational laboratory studies and focuses now on novel treatments for acute myeloid leukemia in Kontro Lab. Read more 👇syopainstituutti.com/researcher-pos…

Dr. Mika Kontro from KontroLab discussed the latest advances in functional screening during the Multi-Omics Driven Precision Hematology Scientific Symposia at #ASH23. The VenEx trial indicates the efficacy of ex vivo venetoclax testing for predicting VEN+AZA responses in AML.

Leukemiasolujen lääkeherkkyystestauksella voidaan ennustaa akuuttia myelooista leukemiaa sairastavien potilaiden hoitovaste uudelle lääkeyhdistelmälle. Kontro Lab tulokset mahdollistavat hoidon kohdentamisen siitä eniten hyötyville potilaille. 📰HUS Helsingin yliopistollinen sairaala: hus.fi/ajankohtaista/…

Drug sensitivity testing on leukemia cells can predict how patients with acute myeloid leukemia (AML) will respond to a new combination therapy. New Kontro Lab results allow treatments to be tailored to those who are most likely to benefit. 📰HUS Helsingin yliopistollinen sairaala: hus.fi/en/newsroom/dr…

Ex vivo venetoclax sensitivity identified treatment responders and correlated with improved outcomes and prolonged survival. Groundbreaking results from the VenEx trial with the Finnish AML Group, University of Helsinki and FIMM HelsinkiUni published now in @BloodJournal

1/4 Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial New study by Kontro Lab and colleagues – study highlights 👇

New findings from our VenEx trial in #AML: venetoclax resistance linked to altered apoptosis & PRAME overexpression. Exploring PRAME-targeted immunotherapy + apoptosis modulators. Grateful for Jane and Aatos Erkko Foundation support to advance this research. #JAES

Data presented at #ESMO25 by Dr Mika Kontro on the Macrophage reprogrammer #bexmarilimab plus azacitidine in myelodysplastic syndrome (BEXMAB) ESMO - Eur. Oncology OncoAlert Naval Daver, M.D. Amer Zeidan MBBS,MHS ‏عامر زيدان